Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid (TXA) to see if it can help reduce bleeding during a procedure known as dilation and evacuation (D&E) for women who are 18 to 24 weeks pregnant and seeking an abortion or managing fetal demise. While D&E procedures are generally safe, excessive bleeding can sometimes occur, and TXA is commonly used in other medical situations to prevent or manage bleeding. This trial aims to find out if giving TXA before the procedure can lower the need for extra treatments to control bleeding and reduce overall blood loss during the D&E.

To participate in this study, women must be between 18 and 24 weeks pregnant, able to understand and sign an informed consent form, and speak either English or Spanish. However, some individuals may not be eligible if they have certain medical conditions, such as a history of blood clots or severe kidney problems. Participants will be randomly assigned to either receive TXA or a placebo (a treatment with no active medication) before their procedure. This trial is still in the planning stages and has not yet begun recruiting participants.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Able to understand and sign informed consent
• • Speaks English or Spanish language,
• • Requesting pregnancy termination or procedural management of fetal demise - Intrauterine pregnancy, 18 weeks 0 days and 24 weeks and 0 days gestation
• Exclusion Criteria:
• • History of or current thromboembolic event (deep vein thrombosis, stroke, pulmonary embolism)
• • History of coagulopathy
• • Anticoagulant use in the preceding five days
• • Severe renal impairment
• • Chorioamnionitis or sepsis
• • Suspected placenta accreta spectrum
• • Prophylactic uterotonics other than oxytocin given (or planned to be given) at the start of the D\&E
• • Known allergic reaction or hypersensitivity to TXA